Trial Profile
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Granulocyte colony-stimulating factors; Nivolumab; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seagen
- 12 Dec 2023 Results (n=154) from part C of this trial in patients with nonbulky early-stage cHL presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results from part b, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to a Seagen media release, results from this study presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition,